Fig. 14

Correlation between PROS1 expression and therapy outcome in clinical studies of immune checkpoint blockade. A Bar plot showing the biomarker relevance of PROS1 compared to standardized cancer immune evasion biomarkers in immune checkpoint blockade (ICB) sub-cohorts. The area under the receiver operating characteristic curve (AUC) was applied to evaluate the predictive performances of the test biomarkers on the ICB response status. B, C Heatmap of PROS1 associations with lymphocyte-mediated tumor killing in CRISPR screens C and outcomes in ICB sub-cohorts (B). D–H 4 glioma cohorts (ca00037@PRECOG, Nutt_Glioma@PRECOG, TCGA, and GSE16011@PRECOG) expression levels of MXD3 were correlated with OS and the level of CTL. I–J CTL expression levels of GSE16011@PRECOG cohort was related with overall survival in PROS1 mRNA expression I and copy number alteration data (J). K 4 drugs were the peak drug candidates based on DSigDB database drug molecules